SNS FiRe Conference Names Immunomic Therapeutics Inc. a 2014 FiReStarter Company
Strategic News Service (SNS) is proud to announce that Immunomic Therapeutics Inc. (ITI) has been selected as a 2014 FiReStarter company, to be featured at the 12th annual Future in Review (FiRe) conference. Described by The Economist as “the best technology conference in the world,” FiRe features global thought leaders in technology and the global economy, including Elon Musk, Mark Hurd, Vint Cerf, Leroy Hood, Patti Grace Smith, Craig Venter, Paul Jacobs, Michael Dell, and many others. FiReStarters are selected based on the strength of their innovations and their potential to bring positive change to the world, and are showcased at an exclusive investor reception at the FiRe conference, in panels throughout the event, and with ongoing relationships introduced and supported by SNS.
Immunomic Therapeutics Inc. (ITI) is a privately held clinical-stage biotechnology company headquartered in Hershey, Pennsylvania, with lab facilities in Rockville, Maryland. ITI is developing next-generation vaccines based on the patented Lysosomal Associated Membrane Protein, or LAMP, technology. Its LAMP-Vax™ vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies.
LAMP emerged from $20 million of NIH-funded research conducted by distinguished scientist Dr. Tom August at the Johns Hopkins University School of Medicine. ITI has the exclusive worldwide license to the LAMP technology patent estate and is commercializing groundbreaking next-generation LAMP DNA vaccines, beginning with allergy, cancer, and infectious disease.
“Vaccines are arguably one of the most important advances in the history of medicine. Now, with LAMP technology, we have the opportunity to change human health once again. We are honored to be invited as a FiReStarter to share our story alongside other groundbreaking companies at this incredible event,” said Bill Hearl, CEO of Immunomic Therapeutics.
“We are delighted to have Immunomic Therapeutics join us as a FiReStarter company for Fire 2014. For years, we have been discussing the future potential of technologies in this field to combat cancer and other diseases, and today, thanks to companies such as theirs, it is happening. Those interested in understanding this revolution in medical treatment, and in meeting the leaders involved, will want to join us at FiRe 2014 and meet the team behind this work,” said Mark Anderson, FiRe Chair and CEO of the Strategic News Service.
Future in Review is a gathering of world-class thought leaders, convened each year with the goal of providing the most accurate look forward in technology. FiRe is a world leader in exploring how technology drives the world economy, and in using technology to solve major social challenges. These goals have been consistently achieved through FiRe’s collaboration across technology-driven industries and through active support from the global FiRe community. Now in its 12th year, FiRe 2014 will take place May 20-23 at the Montage in Laguna Beach, California.
To register for FiRe 2014, and to see bios of speakers and other participants, go to www.futureinreview.com.